<DOC>
	<DOCNO>NCT01335087</DOCNO>
	<brief_summary>OSA may modifiable risk factor cardiovascular disease due association hypertension , stroke , heart attack sudden death . The standard therapy symptomatic OSA continuous positive airway pressure ( CPAP ) . CPAP show effectively reduce snore , obstructive episode daytime sleepiness modestly reduce blood pressure risk factor cardiovascular disease . The overall aim ISAACC determine CPAP reduce risk heart attack , stroke heart failure people OSA admit hospital acute coronary syndrome . Overall objective : To assess impact obstructive sleep apnea ( OSA ) treatment clinical evolution patient acute coronary syndrome ( ACS ) . Primary objective : 1 . To determine continuous positive airway pressure ( CPAP ) treatment reduce rate cardiovascular event ( cardiovascular ( CV ) death , non-fatal event ( acute myocardial infarction ( AMI ) , non-fatal stroke , hospital admission heart failure , new hospitalization ) unstable angina transient ischaemic attack ( TIA ) ) patient ACS co-occurring sleep apnea . Secondary objective : 1 . Determine prevalence OSA patient suffer episode ACS . 2 . Other secondary objective include effect CPAP : - To evaluate composite CV death , myocardial infarction ( MI ) ischaemic stroke . - Components primary composite endpoint - Re-vascularization procedure - To evaluate all-cause death - To evaluate new onset , ECG-confirmed atrial fibrillation arrhythmia - To evaluate newly diagnose diabetes mellitus , accord standard definition - To evaluate OSA symptom ( Epworth Sleepiness Scale ( ESS ) ) - To evaluate quality life patient ACS ( Test EuroQol ( EQ-5D ) . 3 . To establish relationship severity phenotype patient OSA clinical outcome ACS . 4 . To establish relationship CPAP compliance CV event incidence . 5 . To identify biological risk marker allow u establish important mechanism involve cardiovascular complication patient . 6 . To conduct cost-effectiveness analysis diagnosis CPAP treatment patient ACS obstructive sleep apnea .</brief_summary>
	<brief_title>Continuous Positive Airway Pressure ( CPAP ) Patients With Acute Coronary Syndrome Obstructive Sleep Apnea ( OSA )</brief_title>
	<detailed_description>Methods : Study design : multi-centre , open label , parallel , prospective , randomise , control trial . Patients : We include consecutive patient ACS diagnosis evaluate participate Coronary Care Unit . Study sit : IRB Lleida ( Lleida ) , Hospital Son Dureta ( Palma de Mallorca ) , Hospital Clínic ( Barcelona ) , Hospital Germans Tries Pujol ( Barcelona ) , Hospital de Bellvitge ( Barcelona ) , Hospital Sant Pau ( Barcelona ) , Hospital Txagorritxu ( Vitoria ) , Hospital de Cruces ( Bilbao ) , Hospital San Pedro de Alcántara ( Cáceres ) , Hospital Parc Taulí ( Barcelona ) Hospital de Guadalajara ( Guadalajara ) , Hospital de Vallecas ( Madrid ) , Hospital de Yagüe ( Burgos ) , Hospital de Requena ( Valencia ) , Hospital San Juan , ( Alicante ) , Hospital Central de Asturias ( Oviedo ) . Duration study : 3 year . Methodology : During hospital stay assess degree daytime sleepiness ( Epworth Scale ) patient treat Coronary Care Unit diagnosis ACS . The result evaluation define inclusion patient study . Patients ESS score ≤ 10 include study undergo cardio-respiratory polygraphy . Patients AHI ≥ 15 h-1 randomize CPAP treatment conservative . Patients AHÍ &lt; 15 h-1 follow standard management accord cardiovascular protocol evaluate reference group . Therefore , study three group , total 1,864 patient , follow : patient AHI ≥ 15 h-1 randomize CPAP treatment ( Group 1 ) ( n=632 ) conservative treatment ( Group 2 ) ( n=632 ) . Patients AHI &lt; 15 h-1 follow reference group ( Group 3 ) ( n=600 ) . Patients ESS score high 10 exclude study refer sleep unit participate center evaluation . Patients include study monitor follow minimum one year maximum three year . Patients examine time inclusion ( T0 ) , one month ( T1 ) , three month ( T2 ) , six month ( T3 ) , 12 month ( T4 ) every six month thereafter , applicable , follow-up period . Evaluations include ; ) new episode ACS , stroke , TIA , heart failure , hospitalization cardiovascular cause cardiovascular mortality , ii ) biological risk marker involve cardiovascular complication , iii ) evaluation cost-effectiveness diagnosis CPAP treatment patient ACS obstructive sleep apnea .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<criteria>1 . Men woman 18 year old . 2 . Patients admit documented symptom ACS without T segment elevation hospital stay 24h 72 h moment perform polygraphy . 3 . Patients Epworth Sleep Scale score ≤ 10 ( patient without excessive daytime sleepiness ) . 4 . Written inform consent sign . 1 . Previous CPAP treatment OSA diagnosis 2 . Psychophysical inability complete questionnaire . 3 . Presence previously diagnose sleep disorder : narcolepsy , insomnia , chronic sleep deprivation , regular use hypnotic sedative medication restless leg syndrome 4 . Patients &gt; 50 % central apneas presence CheyneStokes Respiration ( CSResp ) 5 . Patients chronic disease : neoplasia , renal failure ( GFR &lt; 30 ml/min ) , severe chronic obstructive pulmonary disease , chronic depression limit chronic disease . 6 . A medical history may interfere study objective , opinion investigator , compromise conclusion . 7 . Any medical factor , social geographical , may jeopardize patient compliance . ( e.g. , alcohol consumption ( 80 gr/day men 60 gr / day woman ) , fixed address , disorientation , history noncompliance ) . 8 . Any process , cardiovascular otherwise , limit life expectancy le one year . 9 . Patients cardiogenic shock poor expectation shortterm outcome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>sleep apnea</keyword>
	<keyword>secondary prevention</keyword>
	<keyword>cardiovascular endpoint</keyword>
</DOC>